NYSE$ENOV

Enovis Corp · Q3 2020 earnings

Q3 2020 earnings · · Investor relations

Briefing

Colfax's Q3 2020 results were reported, demonstrating improved sales momentum and solid profit and cash flow performance.

Colfax reported net sales of $806 million and net income from continuing operations of $16.0 million, or $0.12 per share. Adjusted EPS was $0.41. The Medical Technology segment achieved 2% reported growth, and the company signed an agreement to acquire extremity product lines with annual revenue of $20 million.

  • Reported EPS from continuing operations was $0.12, and adjusted EPS reached $0.41.
  • Medical Technology segment achieved 2% reported growth and 1% organic growth.
  • Fabrication Technology segment's 21% decremental margin contributed to solid company profit and cash flow performance.
  • A definitive agreement was signed to acquire extremity product lines with annual revenue of $20 million.

Headline financials

Total Revenue

$806M

Previous: $847M-4.8%
EPS (adj)

$1.23

Previous: $1.50-18.0%
Capital Expenditures

-$81.6M

Previous: -$100M+18.7%
Free Cash Flow

-$67.4M

Previous: -$89.9M+25.0%
Net Income

$14.2M

Previous: $10.5M+35.5%
Operating Income

$61.9M

Previous: $67.9M-8.7%
Gross Profit

$344M

Previous: $368M-6.5%
Cash & Equivalents

$66.4M

Previous: $127M-47.7%
Total Assets

$7.15B

Previous: $9.59B-25.4%
Stock-Based Comp

$6.96M

Previous: $5.84M+19.2%

Revenue & EPS history

Enovis · Revenue · Quarterly

$806M

Q3 2020-4.8%vs Q3 2019
Beat estimate in 15 of 16 quarters(94%)
ActualEstimate

Revenue by segment

Enovis · $131M total across 1 segment · Q2 2022

  • Reconstructive
    $131M

Forward guidance

The Company expects continued sequential improvement in the fourth quarter of 2020, with adjusted earnings from continuing operations of $0.45 to $0.50 per diluted share.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q3 2020

Historical avgQ3 2020

+1.6%

Avg return

Earnings day

+1.3%

Avg return

5 days after

+0.1%

Avg return

30 days after

52%

33 / 64 earnings

Positive

+21.3%

Q3 2011

Best reaction

-18.7%

Q1 2016

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+9.7%+4.0%-4.5%
Q4 2025+13.8%+13.3%-2.2%
Q3 2025-9.7%+0.1%-14.2%
Q1 2025-2.9%+9.1%-7.2%
Q4 2024-4.9%-10.1%-10.3%
Q3 2024+10.6%+9.3%+10.0%
Q2 2024+4.0%+1.0%+3.5%
Q1 2024-7.5%-5.7%-9.3%
Q4 2023+4.3%+2.0%-0.1%
Q3 2023+4.0%+3.2%+8.8%
Q2 2023-5.6%-8.1%-10.0%
Q1 2023-1.8%-3.7%-3.9%
Q4 2022-9.6%-6.4%-18.9%
Q3 2022-3.4%+7.4%+15.9%
Q2 2022-3.7%-4.4%-17.5%
Q1 2022+5.7%+5.9%+7.4%
Q4 2021+0.9%+2.8%-3.7%
Q3 2021+0.4%-1.4%-14.9%
Q2 2021+3.6%+2.1%+8.5%
Q1 2021-1.1%-5.9%-3.2%
Q4 2020+13.7%+17.2%+16.8%
Q3 2020-4.1%+3.0%+30.8%
Q2 2020+6.8%+13.0%+8.1%
Q1 2020+14.6%+6.6%+33.4%
Q4 2019+2.8%-5.1%-55.3%
Q3 2019+9.6%+11.5%+6.0%
Q2 2019+7.9%+5.3%+15.1%
Q1 2019-5.5%-6.5%-4.7%
Q4 2018+5.3%+6.8%+15.0%
Q3 2018-0.3%+0.8%-12.5%
Q2 2018+5.5%+0.8%+12.9%
Q1 2018+2.2%+5.3%+1.1%
Q4 2017-8.5%-14.2%-11.2%
Q3 2017-12.7%-13.7%-14.0%
Q2 2017+1.1%+0.9%-4.3%
Q1 2017+1.9%+2.4%+7.4%
Q4 2016+2.2%-0.5%-5.0%
Q3 2016+7.8%+5.4%+26.9%
Q2 2016+0.0%-3.2%+3.4%
Q1 2016-18.7%
Q4 2015+18.9%
Q3 2015-6.5%
Q2 2015-5.1%
Q1 2015-0.8%
Q4 2014-0.9%
Q3 2014-5.1%
Q2 2014-6.9%
Q1 2014-3.4%
Q4 2013+7.0%
Q3 2013+0.0%
Q2 2013-0.1%
Q1 2013+4.5%
Q4 2012-5.8%
Q3 2012-2.7%
Q2 2012+5.2%
Q1 2011-5.7%
Q1 2012+1.3%
Q4 2011-1.9%
Q3 2011+21.3%
Q2 2011+16.2%
Q4 2010+16.2%
Q2 2010+16.2%
Q3 2010+1.0%
Q1 2010+0.0%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro